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Background. Exclusion of underlying coronary artery disease (CAD) is essential in the diagnosis of chemotherapy-induced
cardiomyopathy. Presence and severity of CAD can also impact the choice of therapy in cancer patients. The value of cardiac
computed tomographic angiography (CCTA) in this setting has not been reported. Methods. We collected data on the clinical
presentation and indications for CCTA performed from January to December 2008 at the University of Texas MD Anderson
Cancer Center (MDACC). All examinations were performed using a 64-detector scanner. CCTA results and subsequent treatment
decisions were examined. Results. A total of 80 patients underwent CCTA during the study period for the following indications
(not mutually exclusive): cardiomyopathy of unknown etiology in 33 pts (41.3%), chest pain in 32 (40.0%), abnormal stress test
in 16 (20.0%), abnormal cardiac markers in 8 (10.0%), suspected cardiac mass or thrombus in 7 (8.8%). Chemotherapy-induced
cardiomyopathy was diagnosed in 18 pts (22.5%). Severe CAD was detected in 22 pts (27.5%); due to concomitant advanced
cancer or patient refusal, only 12 underwent coronary angiogram. Of these, 4pts (5% of total) underwent coronary artery bypass
grafting. A total of 41 pts (51.3%) had their cancer management altered based on CCTA ﬁndings. Conclusion. CCTA is useful in
evaluating cancer pts with structural heart disease and can have an impact on the managementof cancer and cardiac disease.
1.Introduction
Suspected coronary artery disease (CAD) in patients with
a concurrent malignancy greatly impacts prognosis and
treatment decisions. Faced with both diseases, appropriate
prioritization of care is needed, as some cancer treatments
may be cardiotoxic [1] or lead to blood dyscrasias that
could discourage the use of commonly prescribed cardiac
medications, such as aspirin or heparin products. On the
other hand, planning of cardiac invasive testing requires
clinicians to take into account cancer status and possible
delays in care. Noninvasive coronary anatomical imaging
could therefore help with accurate treatment planning prior
to using invasive strategies.
Exclusion of signiﬁcant obstructive CADin patients with
left ventricular (LV) dysfunction and a prior history of expo-
sure to cardiotoxic chemotherapy agents are both needed
for the diagnosis of chemotherapy-induced cardiomyopathy
(CIC) [2]. In addition, some cancer patients presenting with
other ﬁndings suggestive of structural heart disease may
need an accurate anatomical coronary evaluation. While
invasive coronary angiography (ICA) remains the procedure
of choice in patients with high pretest probability of CAD,
it is not always justiﬁed in those with low to intermediate
suspicion of CAD [3]. It also carries a risk of bleeding or
infectious complications,which may be more likelyin cancer
patients because of blood dyscrasias or immunosuppression.
Ongoing chemotherapy or radiation treatment may also
further delay ICA. There is therefore a need for an accu-
rate noninvasive modality to deﬁne the coronary anatomy
in some cancer patients. Cardiac computed tomographic
angiography (CCTA) is such a modality, and has been
shown to correlate well with ICA [4–6]. Speciﬁcally, its
negative predictive value in excluding CAD in the presence2 Cardiology Research and Practice
Table 1: Baselinecardiac CT angiogrampopulationcharacteristics.
Populationcharacteristics
Age in years (mean ± SD∗) 58.8 ± 12.8
Male gender (%) 45 (56.3)
Known coronary artery disease (%) 7 (8.8)
Hypertension (%) 38 (47.5)
Hyperlipidemia (%) 29 (36.3)
Diabetes mellitus (%) 10 (12.5)
Smoking(%) 5 (6.3)
Previous chest/mediastinal radiation (%) 11 (13.8)
Hematologic malignancy (%) 36 (45.0)
∗SD: standard deviation.
Table 2: Indications for cardiac computed tomographic angiogra-
phy.
CCTA∗ indications N (%)
Left ventricular dysfunction 33 (41.3)
Chest pain/dyspnea 32 (40.0)
Abnormal stress test 16 (20.0)
Abnormal cardiac biomarkers 8 (10.0)
Miscellaneous† 13 (16.3)
∗CCTA: cardiac computed tomographic angiography.
†Miscellaneous indications included suspected tumor and/or thrombus (7
patients)and suspected pulmonary embolism (6 patients).
Indications were not mutuallyexclusive.
of a normal scan is very high [7]. We sought to investigate
the impact of CCTA ﬁndings on cancer treatment decisions.
2.Methods
This retrospective data review study was approved by the
Institutional Review Board (IRB). The clinical presentation
and baseline characteristics of patients who underwent
CCTAbetweenJanuary and December2008at theUniversity
of Texas MD Anderson Cancer Center (MDACC) were
reviewed. The indications for CCTA were collected, as well
as contraindications to invasive angiography, when explicitly
documented. The downstream impact of CCTA results on
patient care decision-making was ascertained for both car-
diac and cancer treatment by review of the medical records.
Speciﬁc diagnostic or therapeutic steps were considered to
be based on CTA results only when medical records explicitly
referenced the CTA results and directly linkedthose decisions
with these ﬁndings. All statistical analysis was performed
using NCSS2001 (Kaysville, Utah).
Prior to CCTA, patients with heart rates above 65
beats per minute on breath holding received beta-blockers
(metoprolol, up to 100mg orally and/or up to 20mg
intravenously). Patients needing heart rate control, but with
contraindications to beta-blockers were managed with oral
calcium-channel blockers. When blood pressure allowed,
patientswere alsogivensublingualnitroglycerinspray0.4mg
immediately prior to undergoing scan. All studies were
performed using a 64-detector scanner (Lightspeed VCT,
Table 3: Relative contraindications for invasive coronary angiogra-
phy.
Invasive angiography contraindications N (%)
Low to moderate probability for CAD∗ 49 (61.3)
Leucopenia/thrombocytopenia 15 (19.2)
Concomitantchemotherapy or radiation 20 (25.0)
≥1 above contraindication 72 (90)
∗CAD: coronary artery disease.
Contraindications are not mutuallyexclusive.
Table 4: Coronary ﬁndings of cardiac computed tomographic
angiography.
CCTA∗ results N (%)
Normal coronary arteries 21 (26.3)
Mild to moderate CAD† 37 (46.2)
Severe‡ CAD 22 (27.5)
∗CCTA: cardiac computed tomographic angiography.
†CAD: coronary artery disease.
‡SevereCADdeﬁnedasluminalnarrowing estimatedtobegreaterthan70%
in at least one vessel or more than 50% left main coronary stenosis.
General Electric Healthcare (GEHC), Milwaukee, WI). A
calcium scoring scan was performed using 2.5mm collima-
tion and 25cm display ﬁeld of view with prospective cardiac
triggering without intravenous contrast material. 150mL
of 320mgI/mL contrast material (iodixanol, Visipaque 320,
GEHC) was administered at 5mL/sec, followed by 50mL
of normal saline at 5mL/sec. A ﬁxed scan delay of 30
seconds was used. Cardiac scanning was performed with
0.625mm collimation using retrospective cardiac gating and
electrocardiographic (ECG) dose modulation. In patients
with signiﬁcant beat to beat heart rate variability or frequent
ectopic beats, ECG dose modulation was not used. Data
was reconstructed at 0.625mm slice thickness and 0.4mm
interval at 70%, 75%, and 80% of the R-R interval for
coronary analysis and a second series at 1.25mm slice
thickness and 1.25mm interval with 10 cardiac phases from
5% to 95% of the R-R interval for functional analysis.
Additional coronary analysis phases were reconstructed as
needed to address motion artifacts on the standard phases.
Examinations were interpreted by a thoracic radiologist
(GG) with 5 years experience in cardiac CT in conjunction
with a cardiologist (ID). Interpretation and postprocessing
were performed using an Advantage workstation (GEHC) or
an iNtuition workstation (TeraRecon, Inc., San Mateo, CA).
Severe CAD was deﬁned as luminal diameter narrowing
estimated to be greater than 70% in at least one vessel
or more than 50% left main coronary stenosis. Coro-
nary stenosis that did not meet the deﬁned criteria for
s e v e r ew a st e r m e dm i l dt om o d e r a t eC A D .Ad i a g n o s i so f
chemotherapy-induced cardiomyopathy was established by
LV dysfunction with prior cardiotoxic chemotherapy expo-
sure and absence of signiﬁcant obstructive CAD. Thrombo-
cytopenia was deﬁned as platelet count less than 50,000 per
μL, and leucopenia as white blood cell count below 4,000 per
μL.Cardiology Research and Practice 3
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Figure 1: 48-year-old female with history of childhood lymphoma treated with mediastinal radiation therapy and anthracycline
chemotherapyatage12,presentedwithfatigueanddecreasedleftventricularejectionfractionbyechocardiogram.CoronaryCTangiography
shows nonobstructive coronary plaques and supports the diagnosis of chemotherapy-induced cardiomyopathy. (a) Curved reformat view
of the right coronary artery (RCA) shows nonocclusive calciﬁc ostial plaque (arrowheads) calciﬁc plaque in the aortic root. The ﬁrst acute
marginal branch is identiﬁed (arrow). Also noted are misregistration artifacts. (b, c) Curved reformat views of the left anterior descending
(LAD) (b) and circumﬂex (c) coronary arteries show calciﬁc plaque (white arrowhead) in the aortic root at the origin of the left main
coronary artery. The ﬁrst diagonal artery (black arrowhead) is identiﬁed on the LAD view (b). The LAD origin (black arrow) and distal
circumﬂex artery continuation (white arrow) are identiﬁed on the circumﬂex view (c). No signiﬁcant narrowing is seen in any of the major
coronary arteries. LA = left atrium. LV = left ventricle. RA = right atrium. RV = right ventricle. Ao = Aortic root. ∗ = breast prosthesis.
Medical management of CAD was deﬁned as treatment
basedoncoronarycalciﬁcationand/orthepresenceofplaque
(which deﬁnesatheroscleroticdisease and therefore identiﬁes
more aggressive secondaryp r e v e n t i o nt a r g e t s ) .
CAD risk factor modiﬁcation was deﬁned as primary
prevention step in absence of demonstrated CAD, which, for
nondiabetic patients, has less stringent criteria.
3.Results
Eighty CCTAs were performed during the ﬁrst year at
our center. Baseline demographics, CAD risk factors and
proportions of hematological malignancies are shown in
Table 1.
The mean age of the patient population was 58.8 ± 12.8
years with 56% males. Hypertension was found in 48% of
the cases, hyperlipidemia in 36% of cases, diabetes mellitus
in 13% and established CAD in 9% of cases. About 45%
of patients had hematological malignancy (leukemia and
lymphoma) whereas the rest had a solid tumor.
The most common indication for obtaining a CCTA was
LV dysfunction (41% of cases) followed by chest pain and
or dyspnea in 40% of the cases (Table 2). About 20% CCTA
was obtained for atypical symptoms with abnormal stress
test and 10% were for atypical symptoms with abnormal
biomarkers. Miscellaneous indications were present in 13
patients (16.3%), including suspected cardiac tumor and/or
thrombus or pulmonary embolism. Indications were not
mutually exclusive and some patients had more than one at
t h et i m eo fC C T A .
Overall, 72pts (90%) had at least one relative con-
traindication to ICA (Table 3). The majority of the patients
(61%) who underwent a CCTA had a low to moderate
pretest probability for CAD. Concomitant radiation or
chemotherapy was present in 25% of cases and rest (19%)
had leucopenia and/or thrombocytopenia.4 Cardiology Research and Practice
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Figure 2: 53-year-old male with metastatic melanoma underwent testing prior to Interleukin-2 (IL-2) therapy. Resting electrocardiogram
and echocardiogram are normal.Dobutamine stress echocardiogram showsinferior wall inducible ischemia.IL-2 is held while coronary CT
angiographyisperformed.BasedonCTﬁndings,IL-2isstartedandgivenuneventfully.(a)Curvedreformatviewoftherightcoronaryartery
shows no atherosclerotic plaque. The conus branch (arrowhead) and sinoatrial nodal branch (arrow) are identiﬁed. (b) Curved reformat
view oftheleft anteriordescending artery showsnoatheroscleroticplaque. Thecircumﬂex artery origin(blackarrowhead)andﬁrst diagonal
artery (white arrowhead) are identiﬁed. (c) Curved reformat view of the circumﬂex coronary artery shows no atherosclerotic plaque. The
ﬁrst obtuse marginal branch (arrowhead) is identiﬁed. LA = left atrium. LV = left ventricle. RA = right atrium. RV = right ventricle. Ao =
Aortic root. PA = pulmonary artery root.
Table 5: Cardiac treatment decisions based on cardiac computed
tomographic angiographyﬁndings.
Cardiac treatment decisions N (%)
ICA∗ only 8 (10)
ICA followed by CABG† 4( 5 )
Medical managementof nonobstructive CAD‡ 30 (37.5)
CAD risk factors modiﬁcation 20 (25)
Management of chemotherapy-induced
cardiomyopathy 18 (22.5)
∗ICA: invasive coronary angiography.
†CABG: coronary artery bypass grafting.
‡CAD: coronary artery disease.
Coronary ﬁndings in CCTA are detailed in Table 4.
Normal coronaries were found in 26.3% of patients, while
mild to moderate CAD was found in 46% and severe CAD in
28%.
Cardiac treatment decisions based on CCTA ﬁndings are
outlined in Table 5.
Due to concomitant advanced cancer or patient refusal,
only 12 out of 22 patients with severe CAD by CCTA under-
went ICA, including 4 patients who eventually underwent
coronaryartery bypassgrafting (CABG).The majorityofthe
patients were managed medically, with 38% of the patients
treated medically for nonobstructive CAD and 23% of
patients treated for chemotherapy-induced cardiomyopathy
(Figure1).In25%ofthecasestheresultofCCTAledtoCAD
risk factor modiﬁcations.
A total of 41pts (51.3%) had their cancer management
altered based on CCTA ﬁndings (Table 6). In 24% of cases,
these ﬁndings directly inﬂuenced the decision to restarting
chemotherapy (Figure 2), while in 9% of cases, they led to
Table 6: Impact of cardiac computed tomographicangiography on
cancer-related treatment decisions.
Cancer treatment decisions N (%)
Proceed with chemotherapy 19 (23.8)
Proceed with stem cell transplant evaluation 8 (10.0)
Proceed with cancer surgery 3 (3.8)
Proceed with radiation therapy 2 (2.5)
Change chemotherapy agents due to cardiomyopathy 7 (8.8)
Hold chemotherapy for invasive coronary angiography 2 (2.5)
a change in chemotherapy agents based on a diagnosis of
chemotherapy-induced cardiomyopathy. In 2.5% of cases,
chemotherapy was temporarily discontinued in order to
proceed with invasive angiography (Figure 3). In 10%
of cases, exclusion of signiﬁcant CAD by CCTA allowed
for stem cell transplant evaluation to proceed. In 4% of
cases, cancer surgery was performed without further cardiac
testing, and 2.5% of cases subsequently started radiation
therapy.
4.Discussion
The present study shows that CCTA can have important
consequences in evaluating cancer patients with suspected
coronary disease, often leading to important decision in the
care of both cancer and heart disease. For more than half
the patients in our study, CCTA had a signiﬁcant impact on
their cancer care. Coexistence of CAD and malignancy often
creates a therapeutic and diagnostic challenge: faced with
two potentially life-threatening conditions, prioritization of
care is paramount. This is because cancer, its treatment, and
complications may render commonly used cardiac tests andCardiology Research and Practice 5
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Figure 3: 61-year-old male with aggressive large B-cell lymphoma developed chest pain after the ﬁrst cycle of chemotherapy.
Electrocardiogram and cardiac enzyme measurements are consistent with NSTEMI. Echocardiography demonstrated a decrease in left
ventricular ejection fraction from a normal baseline to 40%. Due to postchemotherapy thrombocytopenia and leucopenia, an invasive
coronary angiogram could not be obtained. Based on the coronary CT angiogram results, further chemotherapy was placed on hold.
Invasive coronary angiography was performed after recovery of blood counts, followed by coronary artery bypass grafting. Two weeks
later, the patient restarted chemotherapy. (a) Curved reformat view of the right coronary artery shows scattered calciﬁc and noncalciﬁed
atherosclerotic plaque (white arrowheads) with possible occlusion (arrow) near the junction of the mid and distal segments. The conus
branch origin (black arrowhead) is identiﬁed. (b) Curved reformat view of the left anterior descending artery (LAD) shows calciﬁc and
noncalciﬁed atherosclerotic plaque (white arrowheads) in the proximal LAD, with focal near occlusion (arrow) of the LAD at the origin of
the ﬁrst diagonal (D1). Also noted is a mixed ostial left main artery plaque (asterisk). (c) Curved reformat view of the circumﬂex coronary
artery(LCx)andproximalLADshowscalciﬁcandnoncalciﬁedatheroscleroticplaque(arrowheads)intheproximalsegmentsofbothvessels.
The LCx appears occluded at the junction of the proximal and middle segments (arrow). The ostial left mainartery plaque in this projection
appears noncalciﬁed and signiﬁcantly stenotic (asterisk). LA = left atrium. LV = left ventricle. RA = right atrium. RV = right ventricle. Ao
= Aortic root. (d) Invasive angiogram demonstrating same ﬁndings with good correlation. The left main coronary is signiﬁcantly stenosed
(asterisk). The left anterior descending artery shows multiple high grade stenoses (thin arrow) and the left circumﬂex artery is occluded
(thick arrow).
therapies diﬃcult, if not contraindicated. Cancer patients
receiving chemotherapy and experiencing bone marrow
suppression are at higher risk of procedural complications
should they undergo ICA routinely. In other instances,
postoperativestatus,ongoinginfections,orradiationtherapy
may also preclude an invasive approach. In fact, a large
majority of our patients had at least one relative contraindi-
cation to ICA, and as such would have been less likely to be
fully assessed without CCTA. This often leads to the use of
noninvasive stress imaging, traditionally echocardiography
and nuclear imaging for a functional assessment of the
coronaries. However, neither technique is able to show
nonobstructive CAD, nor are they free of false positives [8]
(whichcouldleadtounnecessary ICA[9])andfalsenegatives
(which could fail to correctly identify cancer patients with
signiﬁcant CAD).
CCTA also allowed the accurate diagnosis of CIC, which
has important implications in ongoing cancer care. Current
guidelines for the diagnosis of CIC recommend a coronary
a n g i o g r a mt oe x c l u d et h ep r e s e n c eo fs i g n i ﬁ c a n tC A D .T h e
ACC/AHA guidelines for the diagnosis and management
of heart failure updated in 2009 [2] recognize the use of
noninvasive imaging for detection of ischemia in patients
presenting with heart failure, if revascularization is contem-
plated, with the caveat that stress testing may not reliably
distinguish between ischemic and nonischemic etiologies.6 Cardiology Research and Practice
This emphasizes the need for coronary anatomic assessment
in these patients. In our practice in a tertiary cancer
center,mostpatientswith exposuretopotentiallycardiotoxic
chemotherapy who experience a decrease in LV function
are considered for angiography. Prior to the use of CCTA,
however, many could not undergo ICA, and a conclusive
diagnosis was often lacking. As we have shown, however,
signiﬁcant CAD in the setting of a cardiomyopathy could
accurately be excluded, therefore conﬁrming a suspicion of
CIC in a quarter of our patients (Figure 1).
Noninvasive coronary artery imaging is therefore appeal-
ing in many instances in this patient population, particu-
larly because of its high negative predictive value. Indeed,
CCTA can conclusively demonstrate a normal coronary tree,
therefore alleviating the need for ICA [10]. By accurately
deﬁning the coronary anatomy, CCTA in fact allowed the
prioritization of cancer and cardiac care in our patients, in
some cases, by excluding signiﬁcant CAD suspected either
based on cardiac biomarkers, symptoms, or previous testing
(Figure 2). The advantage of adequate identiﬁcation of
underlying severe CADin certain circumstances would allow
stratiﬁcation of patients who need modiﬁcation of their
chemotherapeuticregimen orwho may beneﬁtfrom concur-
rent treatment with cardioprotective therapeutic agents that
promote positive remodeling, such as β-adrenergic blockers,
angiotensin converting enzyme inhibitors, or angiotensin
receptor blockers. In others, by identifying patients who
needed their cancer care to be put on hold until more press-
ing cardiac issues could be addressed, CCTA also prevented
undue delays in cancer care by seamlessly integrating with
the ﬂow of care.
Our results in a group of cancer patients with low to
intermediate pretest probability for CAD on the basis of
risk factors alone suggest that it may be more prevalent
than suspected. Indeed, we found that nearly a third of pts
had severe CAD, and 5% of total population underwent
CABG. This emphasizes the importance of coordinating
cancer and cardiac care, as both can coexist with equal
s e v e r i t yi nt h es a m ep a t i e n t s .I nf a c t ,s o m ec a s e sw i l l
require the interruption of chemotherapy until the patient
has undergone coronary revascularization (Figure 3). The
addition of noninvasive coronary imaging therefore adds an
invaluable tool in the approach to these diﬃcult cases.
Our study describes a single center experience, and
included patients referred for CCTA. In particular, there is
no control group, and therefore no direct comparison to
other noninvasive modalities (stress testing) can be drawn.
Whether CCTA as a ﬁrst step would compare favorably to
other noninvasive modalities needs further study, particu-
larly as a cost and radiation reduction measure. Although we
reported short-termoutcomesintermsofcancerandcardiac
care, long-term followup will be needed to show deﬁnitive
improvement in overall outcomes.
5.Conclusions
Cardiac computed tomographic angiography is an attrac-
tive imaging modality in cancer patients with suspected
structural heart disease when invasive coronary angiography
may be too risky or impractical and allows improved
coordination of cancer and cardiac care.
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